Gilbert Halley E 4

What Happened

• Director Gilbert Halley received equity awards from Vaxcyte on June 15, 2026: a grant of 2,265 shares and a derivative award of 11,389 units (13,654 total). Both items were reported as acquisitions at $0 per share in the Form 4 filing (i.e., awards/compensation rather than an open‑market purchase).

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-16 (timely filing).
• Reported amounts: 2,265 shares @ $0 and 11,389 derivative shares/units @ $0 (total 13,654).
• Footnote F1: The derivative award represents restricted stock units (RSUs); each RSU converts to one share upon vesting. RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• Footnote F2: A separate award/option tranche has a monthly vesting schedule and also fully vests on the earlier of June 15, 2027 or the day prior to the next annual meeting, subject to acceleration and continuous service.
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: Not flagged as late.

Context

• These entries are grants/awards (compensation) rather than purchases or sales; such awards are routine for executive/director compensation and don’t necessarily signal an immediate trading intent.
• The 11,389 derivative units are RSUs (contingent rights to receive shares on vesting). Vesting conditions and continuous service requirements apply before the shares are delivered.